| Date Filed | Type | Description |
| 08/18/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 04/20/2023 |
8-K
| Quarterly results |
| 03/31/2023 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
| 03/27/2023 |
DEF 14C
| Form DEF 14C - Other definitive information statements: |
| 03/06/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 02/22/2023 |
4
| Farmer Glen A (CFO) has filed a Form 4 on Immune Therapeutics, Inc.|
Txns:
| Bought 409,000 shares
@ $0.045, valued at
$18.4k
|
|
| 01/12/2023 |
PRER14C
| Form PRER14C - Information statements: |
| 01/03/2023 |
8-K
| Quarterly results |
| 12/16/2022 |
PRE 14C
| Form PRE 14C - Other preliminary information statements: |
| 12/15/2022 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 12/15/2022 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 12/15/2022 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 12/15/2022 |
3
| Farmer Glen A (CFO) has filed a Form 3 on Immune Therapeutics, Inc. |
| 12/15/2022 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/09/2022 |
8-K
| Quarterly results |
| 10/12/2022 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 09/27/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"Immune Therapeutics Appoints H. Louis Salomonksy to its Board of Directors ORLANDO, FL, Sept. 27, 2022 — Immune Therapeutics, Inc . , a specialty pharmaceutical company involved in the acquisition, development, and commercialization of pharmaceutical and biotechnology products with a well-defined path to market, today announced the appointment of Louis Salomonsky to the Company’ s Board of Directors. “On behalf of the Board and leadership of Immune, I would like to welcome Louis to Immune’ s Board,” said Dr. Stephen Wilson, CEO of Immune. “Mr. Salomonsky’ s operational leadership, as well as his track record of deal-making and financial acumen, will be instrumental in moving our programs forward.” Commenting on his appointment, Mr. Salomonsky said, “I am excited to join Immune’ s Board to ..." |
|
| 08/31/2022 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 08/24/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/09/2022 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 08/04/2022 |
8-K
| Quarterly results |
| 08/02/2022 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 07/22/2022 |
8-K
| Quarterly results |
| 07/07/2022 |
8-K
| Quarterly results |
| 06/03/2022 |
8-K
| Quarterly results |
| 05/03/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 03/18/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 11/12/2021 |
10-Q
| Quarterly Report for the period ended September 30, 2021 |
| 08/16/2021 |
10-Q
| Quarterly Report for the period ended June 30, 2021 |
| 06/07/2021 |
3
| ROGOFF FAMILY TRUST DTD (Member of 10% owner group) has filed a Form 3 on Immune Therapeutics, Inc. |
| 06/07/2021 |
SC 13D
| Griffin Noreen reports a 8.3% stake in Immune Therapeutics, Inc. |
| 06/07/2021 |
3
| Yanowitz Joel (Member of 10% owner group) has filed a Form 3 on Immune Therapeutics, Inc. |
|